Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia

NCT02293993 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: SGI-110

Sponsor

Otsuka Pharmaceutical Co., Ltd.